Q1 Earnings Estimate for LRMR Issued By HC Wainwright

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Larimar Therapeutics in a report issued on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will post earnings per share of ($0.43) for the quarter. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.54) EPS and FY2027 earnings at ($1.57) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

Several other research analysts have also weighed in on LRMR. Robert W. Baird lowered their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday. Guggenheim reiterated a “buy” rating and issued a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday. Finally, Truist Financial started coverage on Larimar Therapeutics in a research note on Wednesday, January 29th. They set a “buy” rating and a $18.00 price target on the stock. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $20.22.

Larimar Therapeutics Trading Down 2.6 %

NASDAQ LRMR opened at $2.25 on Wednesday. The stock has a market cap of $143.57 million, a PE ratio of -1.96 and a beta of 0.99. Larimar Therapeutics has a twelve month low of $2.19 and a twelve month high of $11.20. The stock has a fifty day simple moving average of $3.11 and a 200-day simple moving average of $5.18.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets purchased a new stake in Larimar Therapeutics during the 4th quarter worth about $25,000. Quest Partners LLC grew its position in shares of Larimar Therapeutics by 171.1% during the third quarter. Quest Partners LLC now owns 9,183 shares of the company’s stock worth $60,000 after buying an additional 5,796 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Larimar Therapeutics during the third quarter worth approximately $71,000. Quarry LP raised its holdings in Larimar Therapeutics by 50.0% in the third quarter. Quarry LP now owns 12,000 shares of the company’s stock valued at $79,000 after acquiring an additional 4,000 shares in the last quarter. Finally, Algert Global LLC purchased a new position in Larimar Therapeutics in the fourth quarter worth approximately $47,000. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.